Article
Pharmacology & Pharmacy
Xing Wang, Yuqi Chen, Jinlei Song, Chao You
Summary: The study compared the efficacy of different monoclonal antibodies against CGRP or its receptor for adult patients with migraine, showing that most drugs performed similarly and were superior to placebo in terms of efficacy, but galcanezumab had slightly different safety profile.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Birgit Vogler, Annette Kuhn, Kimberly D. Mackenzie, Jennifer Stratton, Maria Dux, Karl Messlinger
Summary: Treatment with anti-CGRP antibody fremanezumab effectively prevents chronic and frequent episodic migraines by reducing CGRP release and aversive behavior in rats. Immunohistochemistry and ELISA techniques revealed that fremanezumab treatment significantly lowers the presence of CGRP and CGRP receptor components in the trigeminal ganglion. This reduction in CGRP receptors may contribute to the pain-relieving effects of monoclonal anti-CGRP antibodies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Susan Pederson, David M. Biondi, Brent Allan, Roger Cady, Barbara Schaeffler, Brian Baker, John Latham
Summary: Across five clinical trials, the immunogenicity of eptinezumab was characterized by low titer and transient ADA and NAb responses, with no clinically meaningful impact on efficacy and safety profiles. The onset of detectable ADA occurred at week 8, peaked at week 24, and declined steadily thereafter, regardless of eptinezumab dose level or number of doses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Xing Wang, Dingke Wen, Qiang He, Chao You, Lu Ma
Summary: This study systematically assessed the comparative effectiveness of different CGRP binding monoclonal antibodies (mAbs) for adult migraine patients with prior treatment failure. The results suggest that CGRP mAbs, especially galcanezumab 240 mg, monthly fremanezumab, and eptinezumab 300 mg, seem to be the best choice for the treatment of migraine patients with previous treatment failures.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Dermatology
Twan Sia, Taylor Webb, Shufeng Li, Leon S. Moskatel, Anne Lynn S. Chang
Summary: This exploratory retrospective study examined the effect of CGRP monoclonal antibodies (mAbs) on rosacea in patients with migraines. The majority of patients experienced improvement in rosacea severity after receiving CGRP mAbs. Prospective, placebo-controlled clinical trials are needed to further evaluate the use of CGRP mAbs in rosacea.
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Article
Clinical Neurology
Shiho Suzuki, Keisuke Suzuki, Tomohiko Shiina, Saro Kobayashi, Koichi Hirata
Summary: We report a case of improvement of both migraine and RLS symptoms after treatment with CGRP monoclonal antibody.
JOURNAL OF THE NEUROLOGICAL SCIENCES
(2022)
Article
Clinical Neurology
Marcello Silvestro, Ilaria Orologio, Simona Bonavita, Fabrizio Scotto di Clemente, Carla Fasano, Alessandro Tessitore, Gioacchino Tedeschi, Antonio Russo
Summary: The study showed that CGRP-mAbs could effectively reduce the frequency, intensity, and duration of menstrual migraine attacks in MRM patients who had previous treatment failures, as well as significantly improve the responsiveness to painkillers, indicating the potential of CGRP-mAbs as a safe and effective preventive treatment for menstrual migraines.
Review
Clinical Neurology
Betel Tesfay, William Kristian Karlsson, Rogelio Dominguez Moreno, Debbie L. Hay, Anders Hougaard
Summary: The purpose of this study was to provide an overview of clinical studies on CGRP measurements in body fluids of migraine patients and to discuss the validity of CGRP measurement as a clinical biomarker of migraine. Several studies have reported increased CGRP levels in various body fluids of migraine patients, suggesting that CGRP may be a feasible biomarker. However, inconsistencies and methodological challenges in measuring CGRP levels exist. CGRP measurements may have potential as biomarkers for predicting response to migraine therapy.
CURRENT OPINION IN NEUROLOGY
(2022)
Article
Clinical Neurology
Michael Lowe, Lesley Murray, Alok Tyagi, George Gorrie, Sarah Miller, Krishna Dani
Summary: This study presents the experience of using erenumab in a tertiary headache centre for the treatment of chronic migraine. The results demonstrate that erenumab can effectively reduce headache days, particularly in those with daily headaches. However, some patients may experience adverse effects, leading to discontinuation of treatment.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Hyoung Cheol Lee, Soohyun Cho, Byung-Kun Kim
Summary: This study identified everyday headache, presence of depression, and absence of accompanying symptoms as significant predictors of a poor response to galcanezumab treatment in patients with chronic migraine.
NEUROLOGICAL SCIENCES
(2023)
Article
Clinical Neurology
Cinzia Valeria Russo, Francesco Sacca, Simone Braca, Mattia Sansone, Angelo Miele, Antonio Stornaiuolo, Roberto De Simone
Summary: This study evaluated the efficacy of erenumab, fremanezumab, or galcanezumab in treating vestibular migraine patients. The results showed excellent response to treatment, with a reduction in frequency of vertigo and headache in the majority of patients. The use of anti-CGRP monoclonal antibodies may be effective in the treatment of vestibular migraine.
Article
Biotechnology & Applied Microbiology
Laurent David, Michelle Scalley-Kim, Andrea Olland, Andre White, Kira Misura
Summary: This study utilized X-ray crystallography, computational alanine scanning, and molecular dynamics to elucidate the mechanism of action and binding properties of eptinezumab to CGRP. The complex demonstrated extensive contact between eptinezumab and CGRP, with a high ligand-binding surface area dominated by aromatic residues. Structural and conformational changes in eptinezumab during binding contribute to the specificity, durability, and strength of the interaction, supporting the rapid and sustained migraine preventive effect observed in clinical studies.
Article
Clinical Neurology
Fenne Vandervorst, Laura Van Deun, Annelies Van Dycke, Koen Paemeleire, Uwe Reuter, Jean Schoenen, Jan Versijpt
Summary: The new class of migraine preventive drugs, monoclonal antibodies targeting the CGRP pathway, demonstrates efficacy comparable to or higher than currently used preventive drugs, supported by robust evidence from large randomized clinical trials. Their excellent tolerability and emerging long-term safety data suggest an unprecedented efficacy-over-adverse-effect profile, adding value to migraine prevention.
JOURNAL OF HEADACHE AND PAIN
(2021)
Article
Clinical Neurology
Bo Hu, Gang Li, Xiaohong Li, Shan Wu, Tingmin Yu, Xiang Li, Hongru Zhao, Zhihua Jia, Junpeng Zhuang, Shengyuan Yu
Summary: This study evaluated the efficacy and safety of galcanezumab in patients with episodic migraine from China, India, and Russia. The results showed that monthly galcanezumab treatment significantly reduced migraine headache days and improved patients' quality of life, with good tolerability.
JOURNAL OF HEADACHE AND PAIN
(2022)
Article
Clinical Neurology
Jiying Zhou, Lianmei Zhong, Debashish Chowdhury, Kirill Skorobogatykh, Guogang Luo, Xiaosu Yang, Mingjie Zhang, Lingli Sun, Hui Liu, Chenxi Qian, Shengyuan Yu
Summary: The open-label extension (OLE) study of the phase 3 randomized PERSIST study showed that galcanezumab, a humanized anti-CGRP monoclonal antibody, was effective and well-tolerated for up to 6 months in patients with episodic migraine from China, India, and Russia.
JOURNAL OF HEADACHE AND PAIN
(2023)